Clinical Trials Browser

Phase 1/2 × fluzoparib × Thoracic × Clear all

NCT07141771 2025-08-26

An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing

Phase 1/2 Not yet recruiting

SCLC, Extensive Stage

NCT04659785 2020-12-09

A Study of Fluzoparib Combined With Apatinib as Second-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer（FA-ES-SCLC）

Phase 1/2 Unknown

Small Cell Lung Carcinoma